异基因造血干细胞移植治疗多发性骨髓瘤研究进展

异基因造血干细胞移植（allo-HSCT）是唯一可能治愈多发性骨髓瘤（MM）的方法，但较高的移植相关死亡（TRM）率限制了其应用。尽管减低强度预处理（RIC）的allo-HSCT降低了TRM率，但其疗效仍不优于自体造血干细胞移植（auto—HSCT）。因此需要进一步研究降低移植毒性和促进移植物抗骨髓瘤（GVM）效应的新策略，以便使RIC allo-HSCT更加安全有效。文章对目前allo—HSCT在MM中的研究进展进行了综述。

Research progress of allogeneic stem cell transplantation in multiple myeloma patients

Allogeneic stem cell transplantation （allo-HSCT） is probably the only treatment for multiple myeloma （MM） with a curative potential. However, the application of allo-HSCT is limited by the high transplant-related mortality （TRM）. Although the introduction of reduced intensity conditioning （RIC） has lowered the TRM associated with myeloablative conditioning, there is no improvement in survival of allo-RIC compared to autologous stem cell transplantation （auto-HSCT）. New strategies are discussed with the aim of lowering transplant toxicity and boosting the graft-versus-myeloma effect, and these are urgently needed to make allo-RIC safer and more effective for myeloma patients. In this review, results from studies of allo-HSCT in MM are presented.